Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial

Background: Nonalcoholic steatohepatitis (NASH) is associated with increased cardiovascular risk and mortality. No US Food and Drug Administration (FDA) approved therapies for NASH are available; clinical trials to date have not yet systematically assessed for changes in cardiovascular risk. This st...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Steven C. Lin, Brandon Ang, Carolyn Hernandez, Ricki Bettencourt, Rashmi Jain, Joanie Salotti, Lisa Richards, Yuko Kono, Archana Bhatt, Hamed Aryafar, Grace Y. Lin, Mark A. Valasek, Claude B. Sirlin, Sharon Brouha, Rohit Loomba
Format:	Artigo
Jezik:	Inglês
Izdano:	SAGE Publishing 2016-03-01
Serija:	Therapeutic Advances in Gastroenterology
Online dostop:	https://doi.org/10.1177/1756283X15621232
Oznake:	Označite Brez oznak, prvi označite!